Product Program year 2025 Source: CMS Open Payments

Alyftrek

Drug Cystic Fibrosis

NDC 51167-121-01

Open in the dashboard

General payments

$86,719

530 payments

Research payments

$0

0 payments

Through program year 2025, $86,719 in general payments and $0 in research payments were reported against Alyftrek (Cystic Fibrosis).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

1 row
Year Kind Amount Payments
2025 General $86,719 530

Breakdown

Who paid General payments · program year 2025
  1. Vertex Pharmaceuticals Incorporated $86,719 530 payments
Top recipients General payments · program year 2025
  1. Patricia Eshaghian Pulmonary Disease · Los Angeles, CA $14,645 17% · 7 payments
  2. Patricia Walker Pulmonary Disease · New York, NY $8,740 10% · 7 payments
  3. Joan Decelie-Germana Pediatrics · Great Neck, NY $7,076 8% · 9 payments
  4. John Dickinson Pulmonary Disease · Omaha, NE $6,512 8% · 7 payments
  5. Anju Singhal Critical Care Medicine · Falls Church, VA $6,119 7% · 11 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Pulmonary Disease Internal Medicine $39,286 47% · 36 practitioners
  2. Pediatric Pulmonology Pediatrics $19,398 23% · 91 practitioners
  3. Pediatrics $12,989 15% · 14 practitioners
  4. Critical Care Medicine Internal Medicine $6,225 7% · 5 practitioners
  5. Nurse Practitioner, Pediatrics Nurse Practitioner $2,114 3% · 33 practitioners

The top 5 of 30 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. New York $25,115 29% · 11 recipients
  2. California $22,765 26% · 33 recipients
  3. Nebraska $7,072 8% · 5 recipients
  4. Virginia $6,541 8% · 20 recipients
  5. Pennsylvania $5,502 6% · 6 recipients

The top 5 of 36 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

530 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record